Rheumatology · Clinical trials
Systemic Sclerosis (Scleroderma) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About systemic sclerosis (scleroderma) — and why its trials are hard
Systemic sclerosis is a rare, heterogeneous autoimmune connective-tissue disease defined by immune dysregulation, small-vessel vasculopathy, and progressive fibrosis of skin and internal organs. Subsets include limited and diffuse cutaneous forms; major causes of death are interstitial lung disease (ILD) and pulmonary arterial hypertension. Autoantibodies (anti-centromere, anti-Scl-70/topoisomerase, anti-RNA polymerase III) aid classification and prognosis. Treatment is organ-directed and historically relied on immunosuppression such as mycophenolate and cyclophosphamide, with few approved options. The landscape improved for SSc-ILD: nintedanib, an antifibrotic tyrosine kinase inhibitor, was approved in 2019 after SENSCIS slowed lung-function decline, and tocilizumab (IL-6 receptor blockade) gained approval in 2021 for SSc-ILD despite its pivotal trial missing the skin primary endpoint, because it preserved forced vital capacity. Many programs targeting skin fibrosis have failed, including tocilizumab for mRSS, riociguat, and lenabasum, reflecting the difficulty of reversing established fibrosis and the insensitivity of skin-score endpoints. Autologous hematopoietic stem-cell transplantation benefits selected high-risk patients. Overall options remain limited and unmet need is high.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Nintedanib (Ofev) | 2019 | SSc-associated interstitial lung disease (SSc-ILD); antifibrotic tyrosine kinase inhibitor | SENSCIS (phase 3) | Annual rate of FVC decline over 52 weeks | -52.4 mL/yr vs -93.3 mL/yr placebo (difference ~41 mL/yr, p=0.04) |
| Tocilizumab (Actemra) | 2021 | Slowing lung-function decline in adults with SSc-ILD (IL-6 receptor antibody) | focuSSced (phase 3) | Change in modified Rodnan Skin Score (mRSS) at week 48 (primary, not met); FVC preserved as key secondary | Primary mRSS endpoint not met; FVC decline attenuated (mean change ~-0.4% vs -4.6% predicted), supporting ILD approval |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in systemic sclerosis (scleroderma) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Tocilizumab (skin endpoint) — faSScinate (phase 2) and focuSSced (phase 3) | Failed to significantly improve modified Rodnan Skin Score (mRSS) as primary endpoint | Skin fibrosis proved resistant and mRSS insensitive; lung benefit rather than skin benefit ultimately drove the SSc-ILD approval |
| Riociguat (soluble guanylate cyclase stimulator) — RISE-SSc (phase 2b) | Did not significantly reduce mRSS progression in early diffuse cutaneous SSc | No meaningful antifibrotic skin effect; development for skin fibrosis not pursued |
| Lenabasum (CB2 agonist) — RESOLVE-1 (phase 3) | Failed to meet primary endpoint (ACR CRISS) versus placebo | High background immunosuppression and large placebo response obscured any drug effect |
Choosing the right endpoint
Primary endpoints that matter in systemic sclerosis (scleroderma) trials
- FVC (forced vital capacity) — Rate of lung-function decline; primary in SENSCIS and pivotal for ILD approvals
- Modified Rodnan Skin Score (mRSS) — Palpation-based skin thickness score; a frequently missed and insensitive skin endpoint
- ACR CRISS — Composite Response Index in diffuse cutaneous SSc combining organ measures and patient outcomes
- HRCT lung fibrosis extent — Imaging measure of ILD burden and progression
How iNGENū runs systemic sclerosis (scleroderma) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Systemic Sclerosis (Scleroderma) clinical trials — FAQs
What drugs are approved for systemic sclerosis?
Why was tocilizumab approved despite missing its primary endpoint?
Why do so many scleroderma skin trials fail?
Ready to discuss your systemic sclerosis (scleroderma) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal